SGLT-2 inhibitor dapagliflozin improves left ventricular diastolic function and reduces circulating inflammatory markers in HFpEF patients: a retrospective cohort study.
OBJECTIVE This study sought to evaluate the efficacy of sodium-glucose cotransporter 2 (SGLT-2) inhibitor Dapagliflozin in ameliorating left ventricular diastolic function (LVDF) and attenuating systemic inflammatory biomarkers in patients with heart failure with preserved ejection fraction (HFpEF). METHODS A total o...